Artificial Disc Replacement denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for artificial disc replacement are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Artificial Disc Replacement
## Why Humana Denied Artificial Disc Replacement as Duplicate Therapy
A duplicate-therapy denial for artificial disc replacement (ADR) typically arises when Humana's system identifies that a spinal procedure or related treatment has recently been approved, is currently active, or is being requested alongside ADR. The insurer's logic is that you are already receiving — or have recently received — a procedure that addresses the same clinical problem. Most commonly this surfaces when ADR is requested alongside or shortly after a spinal fusion at the same or an adjacent level, or after conservative-care authorization.
This denial is frequently incorrect in clinical terms. ADR and spinal fusion are not interchangeable procedures: they have different indications, different biomechanical objectives (motion preservation versus motion elimination), different candidacy criteria, and distinct FDA-approved device labeling. A spine surgeon's recommendation for ADR over fusion is a clinical judgment, not a duplication. The appeal must establish that distinction clearly.
## Your Federal Appeal Rights
- Internal appeal: Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair review by a clinical peer (typically an orthopedic or neurosurgical specialist) not involved in the original denial. File in writing within the deadline on your denial letter.
- External review: After an adverse internal outcome, you may request independent external review by an IRO. Federal law provides approximately four months from the original denial; your plan documents control the exact window. The IRO's decision is binding.
- Expedited review: Available when standard timelines would jeopardize your health or create significant impairment; typically resolved within 72 hours.
## What to Gather
1. Identification of the "duplicate" procedure: Obtain from Humana a clear statement of what procedure they consider to be duplicated by ADR. This is essential — your appeal rebuttal depends on knowing exactly what they are comparing. 2. Spine surgeon's operative plan and rationale: A detailed operative note or pre-surgical consultation documenting why ADR is recommended over fusion and why they are clinically distinct for this patient at this spinal level. 3. Imaging documentation: Current MRI, CT, or X-ray reports confirming the diagnosis and the level(s) being treated. 4. FDA device labeling: The approved indications for the specific ADR device your surgeon intends to use. This documents the procedure's distinct clinical indication. 5. Conservative-care history: Documentation of all non-surgical treatments tried, with dates and outcomes, confirming surgical candidacy. 6. Applicable guideline reference: Your surgeon's letter may reference applicable North American Spine Society (NASS) or similar organizational guidance on ADR candidacy.
## Criteria-Mapping Structure
In your appeal, create a two-column table: left column identifies the procedure Humana claims is duplicated; right column documents — point by point — the clinical distinctions between that procedure and ADR in your specific case (different spinal levels, different biomechanical goal, different device, different clinical indication). Attach the FDA device label as a supporting exhibit.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →